Prevalence and genotype distribution of HPV infection among women in Xiamen, China
暂无分享,去创建一个
Xiaomei Huang | Wenbo Wang | Yun-sheng Ge | Xiaolu Chen | Lutan Zhang | Jian Zhang | Ye Shen | Ya-ming Huang
[1] Xuewei Zhuang,et al. HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic , 2023, Human vaccines & immunotherapeutics.
[2] Chao Zhao,et al. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China , 2023, Frontiers in Immunology.
[3] M. Poljak,et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis , 2022, The Lancet. Global health.
[4] Ruili Sun,et al. Prevalence and distribution of human papillomavirus genotypes among women attending gynecology clinics in northern Henan Province of China , 2022, Virology Journal.
[5] Hongbo Wang,et al. Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China , 2021, Virology Journal.
[6] Yi Huo,et al. Prevalence and genotype distribution of human papillomavirus infection among women aged 30–65 years in Xi’an, China: a population-based study of 14,655 women , 2021, Human vaccines & immunotherapeutics.
[7] Yufei Xiao,et al. Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016–2020 , 2021, Virology journal.
[8] Jie Wu,et al. Prevalence and Genotype Distribution of Human Papillomavirus Among Healthy Females in Beijing, China, 2016–2019 , 2021, Infection and drug resistance.
[9] J. Park,et al. Multiple Human Papilloma Virus (HPV) Infections Are Associated with HSIL and Persistent HPV Infection Status in Korean Patients , 2021, Viruses.
[10] J. Su,et al. Prevalence and genotype distribution of high‐risk HPV infection among women in Beijing, China , 2021, Journal of medical virology.
[11] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[12] Y. Qiao,et al. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China , 2020, JAMA oncology.
[13] Ying Lu,et al. Incidence, persistence and clearance of cervical human papillomavirus among women in Guangdong, China 2007-2018: A retrospective cohort study. , 2020, Journal of infection and public health.
[14] Guosong Shen,et al. Prevalence and genotype distribution of human papillomavirus infection in Huzhou City, eastern China, 2018-2019. , 2020, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[15] Zhaoli Zhou,et al. Characteristics of human papillomavirus infection among women with cervical cytological abnormalities in the Zhoupu District, Shanghai City, China, 2014–2019 , 2020, Virology Journal.
[16] Y. Huang,et al. Prevalence of human papillomavirus infection and type distribution among Uyghur females in Xinjiang, northwest China , 2020, Oncology letters.
[17] J. Zhao,et al. Comparison of the detection rate of cervical lesion with TruScreen, LBC test and HPV test: A Real-world study based on population screening of cervical cancer in rural areas of China , 2020, PloS one.
[18] Lanlan Wei,et al. Epidemiology and persistence of cervical human papillomavirus infection among outpatient women in Heilongjiang province: A retrospective cohort study , 2020, Journal of medical virology.
[19] Yanfang Jiang,et al. HPV genotypic spectrum in Jilin province, China, where non-vaccine-covered HPV53 and 51 are prevalent, exhibits a bimodal age-specific pattern , 2020, PloS one.
[20] Jintao Wang,et al. Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women , 2019, Human vaccines & immunotherapeutics.
[21] D. Ma,et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. , 2019, Cancer letters.
[22] T. Zuo,et al. The prevalence, trends, and geographical distribution of human papillomavirus infection in China: The pooled analysis of 1.7 million women , 2019, Cancer medicine.
[23] K. Smith-McCune,et al. Cervical Cancer Screening: More Choices in 2019. , 2019, JAMA.
[24] A. Burchell,et al. Human papillomavirus viral load and transmission in young, recently-formed heterosexual couples. , 2019, The Journal of infectious diseases.
[25] Kemin Li,et al. The distribution and prevalence of human papillomavirus in women in mainland China , 2019, Cancer.
[26] Lingbo Jiang,et al. HPV prevalence and genotype distribution among women in Shandong Province, China: Analysis of 94,489 HPV genotyping results from Shandong’s largest independent pathology laboratory , 2019, PloS one.
[27] S. Kulasingam,et al. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. , 2018, The Lancet. Oncology.
[28] Y. Meng,et al. Prevalence characteristics of single and multiple HPV infections in women with cervical cancer and precancerous lesions in Beijing, China , 2018, Journal of medical virology.
[29] Youzhong Zhang,et al. Prevalence and Genotype Distribution of Human Papillomavirus in Invasive Cervical Cancer, Cervical Intraepithelial Neoplasia, and Asymptomatic Women in Southeast China , 2018, BioMed research international.
[30] Ning Wang,et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. , 2018, The Lancet. Global health.
[31] Jichun Zhou,et al. Prevalence of human papillomavirus infection among 71,435 women in Jiangxi Province, China. , 2017, Journal of infection and public health.
[32] R. Winer,et al. Natural History of HPV Infection across the Lifespan: Role of Viral Latency , 2017, Viruses.
[33] Xianjin Zhu,et al. Epidemiology of Humanpapilloma virus infection among women in Fujian, China , 2017, BMC Public Health.
[34] Kemin Li,et al. Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China , 2017, Oncotarget.
[35] R. Burk,et al. Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention , 2017, Expert review of molecular diagnostics.
[36] Ruoran Li,et al. Human papillomavirus vaccine approval in China: a major step forward but challenges ahead. , 2016, The Lancet. Infectious diseases.
[37] J. Nie,et al. Multiple human papillomavirus infections and type‐competition in women from a clinic attendee population in China , 2016, Journal of medical virology.
[38] T. He,et al. Prevalence and genotype distribution of HPV infection among women in Ningbo, China , 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[39] Eileen F. Dunne,et al. HPV and HPV-associated diseases. , 2013, Infectious disease clinics of North America.
[40] Y. Qiao,et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study , 2013, Cancer Causes & Control.
[41] Karen Canfell,et al. The burden of cervical cancer in China: Synthesis of the evidence , 2012, International journal of cancer.
[42] L. Cai,et al. Prevalence of genital human papillomavirus infection and genotypes among women from Fujian province, PR China. , 2010, European journal of obstetrics, gynecology, and reproductive biology.
[43] M. Stanley. Pathology and epidemiology of HPV infection in females. , 2010, Gynecologic oncology.
[44] Vogel Ln. Epidemiology of human papilloma virus infection. , 1992, Seminars in dermatology.
[45] C Milligan,et al. Screening for cervical cancer. , 1975, The American journal of nursing.